Drug class
Serotonergic antiseizure medicine; serotonin-releasing agent and 5-HT receptor modulator
Mechanism of action
The precise mechanism by which fenfluramine reduces seizures in Dravet syndrome and Lennox-Gastaut syndrome is not fully established. It enhances serotonergic signalling, including activity at 5-HT receptors, and may also modulate sigma-1 receptor signalling.
General use cases
- Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older
- Treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older; use requires product-specific cardiac monitoring because of valvular heart disease and pulmonary arterial hypertension risks
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
